PTC治療 PTCT 深 滬
等待開盤 07-18 09:30:00 美东时间
48.53
+0.390
+0.81%
華盛通- 最 高49.45
- 今 開48.35
- 成交量 55.27万股
- 最 低 48.26
- 昨 收 48.14
- 總市值 38.46亿
- 52周最高 58.38
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 29.015
- 委 比 -13.76%
- 總股本 7925.70万
- 歷史最高 78.72
- 量 比 0.55
- 振 幅 2.47%
- 歷史最低 4.03
- 每 手 1
- 風險率 6.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PTC Therapeutics’ Gene Therapy Trial: A Promising Update for Investors
PTC Therapeutics (($PTCT)) announced an update on their ongoing clinical study....
今天 00:22
PTC Therapeutics Advances PKU Treatment with Sepiapterin Study
PTC Therapeutics (($PTCT)) announced an update on their ongoing clinical study....
今天 00:21
PTC Therapeutics’ Vatiquinone Study: A Long-Term Commitment to Friedreich Ataxia
PTC Therapeutics (($PTCT)) announced an update on their ongoing clinical study....
07-17 00:16
POET Technologies Announces US$25 Million Offering
POET Technologies Inc. announces a non-brokered public offering of 5 million units at US$5.00 per Unit, raising US$25 million gross proceeds. Each Unit includes one common share and a warrant exercisable at C$8.16 for five years. The Offering is expected to be fully subscribed by a Canadian institutional investor and is subject to regulatory approvals. Net proceeds will fund working capital and general corporate purposes.
07-07 12:15
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggre...
06-20 04:30
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Truist Securities Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $80
Truist Securities analyst Joon Lee initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and announces Price Target of $80.
06-17 22:28
Citi Remains a Hold on PTC Therapeutics (PTCT)
Citi analyst Geoff Meacham reiterated a Hold rating on PTC Therapeutics (PTCT –...
06-03 01:45
美股大行评级 | 潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
05-28 09:04
SEALSQ Stock Is Soaring Tuesday: What's Going On?
SEALSQ stock is trading higher Tuesday after the company announced an investment in Wecan Token.
05-27 23:01
